AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A method of preventing or ~~treating~~otherwise reducing the risk of development of insulin-dependent diabetes in a subject ~~comprising introducing into said subject an antigen presenting cell (APC) which presents pro-insulin~~, said method comprising collecting a sample of hemopoetic stem cells (HSCs) and/or hemopoetic progenitor cells (HPCs) from said subject, introducing into one or more HSCs and/or HPCs genetic material encoding ~~said~~ pro-insulin or an immunogenic homolog, part, fragment or portion thereof under conditions wherein said genetic material is expressed so that the HSCs and/or HPCs produce said pro-insulin or said immunogenic homolog, part, fragment or portion thereof, introducing to the subject the HSCs and/or HPCs producing said pro-insulin, wherein said HSCs and/or HPCs develop into antigen presenting cells (APCs) expressing said pro-insulin.

2. (Currently amended) The method of claim 1, wherein said ~~APC is~~ APCs are selected from a dendritic ~~cell~~cells, ~~B-lymphocyte~~B-lymphocytes, epithelial ~~cell~~cells, ~~monocyte~~monocytes and ~~macrophage~~macrophages.

3. (Currently amended) The method of claim 2, wherein said ~~APC is a dendritic cell~~APCs are dendritic cells.

4. (Original) The method of claim 1, wherein said subject is selected from the group consisting of a human, primate, sheep, horse, cow, donkey, pig, goat, rabbit, mouse, rat, guinea pig, dog, cat, bird, chicken, bantams, geese and turkeys.

5. (Original) The method of claim 1, wherein said subject is a human.

6. (Currently amended) The method of claim 1, wherein said HSCs or HPCs are ~~cell is~~ derived from bone marrow from the hip bone, bone marrow, cord blood, blood from liver, blood

from a tissue and PBMCs.

7. (Currently amended) The method of claim 6, wherein said ~~cell is~~ HSCs or HPCs are derived from bone marrow from a hip bone.

8. (Original) The method of claim 1, wherein said proinsulin is of human origin.

9. (Canceled)

10. (Currently amended) A method for ~~treating or~~ preventing or otherwise reducing the risk of developing insulin-dependent diabetes in a subject comprising, (a) collecting a sample of hemopoetic stem cells (HSCs) and/or hemopoetic progenitor cells (HPCs) from a subject; (b) introducing into one or more HSCs and/or HPCs genetic material encoding pro-insulin or an immunogenic homolog, part, fragment or portion thereof under conditions wherein said genetic material is expressed so that the HSCs and/or HPCs produce said pro-insulin or an immunogenic homolog, part, fragment or portion thereof; and (c) infusing or introducing ~~said~~the genetically modified cells into said subject.

11. (Original) The method of claim 10, wherein said HSCs and/or HPCs undergo cytokine mediated mobilisation.

12. (Original) The method of claim 10, wherein said subject is selected from the group consisting of human, primate, sheep, horse, cow, donkey, pig, goat, rabbit, mouse, rat, guinea pig, dog, cat, bird, chicken, bantams, geese and turkeys.

13. (Original) The method of claim 10, wherein said subject is a human.

14. (Original) The method of claim 10, wherein said HSCs and HPCs are derived from a source selected from bone marrow from the hipbone, bone marrow, cord blood, blood from liver, blood from a tissue and PBMCs.

15. (Original) The method of claim 14, wherein said HSCs and HPCs are derived from bone marrow from a hipbone.

16. (Original) The method of claim 10, wherein said proinsulin is of human origin.

17-25. (Canceled)